Sugi Predict

Sugi Predict / Compounds / SCHEMBL12778474

SCHEMBL12778474

SCHEMBL12778474

C/C(=N\OCc1ccc(C#N)cc1)c1cc(Cl)ccc1NS(=O)(=O)C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ MAPT P10636 2/20 0.42
▸ SLC22A12 Q96S37 1/20 0.41
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ PPARA Q07869 1/20 0.39
▸ DDR1 Q08345 1/20 0.37
▸ PSEN1 P49768 2/20 0.36
▸ PSEN2 P49810 2/20 0.36
▸ APH1B Q8WW43 2/20 0.36
▸ NCSTN Q92542 2/20 0.36
▸ APH1A Q96BI3 2/20 0.36
▸ PSENEN Q9NZ42 2/20 0.36
▸ CA12 O43570 1/20 0.35
▸ TRPA1 O75762 1/20 0.35
▸ AKR1B1 P15121 1/20 0.35
▸ PTGS1 P23219 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12778373 0.92 MEN1 (0.40) NPC1L3MBTL1RAB9AMAPTMEN1
SCHEMBL12778503 0.89 SLC22A12 (0.39) NPC1L3MBTL1RAB9ASMN1; SMN2MAPT
SCHEMBL12778366 0.88 CCR9 (0.42) L3MBTL1MAPTMEN1KMT2APPARA
SCHEMBL12778385 0.88 L3MBTL1 (0.39) NPC1L3MBTL1RAB9ASMN1; SMN2MAPT
SCHEMBL12778384 0.88 NPC1 (0.43) NPC1L3MBTL1RAB9ASMN1; SMN2PPARA
SCHEMBL12778425 0.86 PTGS1 (0.37) NPC1L3MBTL1RAB9ASMN1; SMN2MAPT
SCHEMBL12778378 0.86 NPC1 (0.45) NPC1RAB9APPARAPTGS1PTGS2
SCHEMBL12778489 0.85 NPC1 (0.45) NPC1L3MBTL1RAB9ASMN1; SMN2MAPT
SCHEMBL12778576 0.85 SLC22A12 (0.40) SLC22A12PPARATRPA1PTGS1PTGS2
SCHEMBL12778337 0.85 CYP19A1 (0.45) NPC1RAB9ASMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7906538-B2 Parasiticides; nematocides; crop protection SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) 2011-03-15 — — US disclosed
US-20080262048-A1 CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES SCHERING-PLOUGH ANIMAL HEALTH CORPORATION 2008-10-23 — — US disclosed
US-7312248-B2 Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) 2007-12-25 — — US disclosed
US-7312248-B2 Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) 2007-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262048-A1 CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES TRHDE, EPX, EPHX1 NPC1 4153/4885L3MBTL1 74/4885RAB9A 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.